Next Article in Journal
Complexes of Gold(III) with Hydrazones Derived from Pyridoxal: Stability, Structure, and Nature of UV-Vis Spectra
Previous Article in Journal
Emerging Roles of Vitamin B12 in Aging and Inflammation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 9
10.3390/ijms25095045
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis

by
Miriam Dawidowicz
1,*,
Agnieszka Kula
1,
Sylwia Mielcarska
2,
Elżbieta Świętochowska
2 and
Dariusz Waniczek
1,*
1
Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Katowice, Poland
2
Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Zabrze, Poland
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(9), 5045; https://doi.org/10.3390/ijms25095045
Submission received: 8 April 2024 / Revised: 27 April 2024 / Accepted: 2 May 2024 / Published: 6 May 2024
(This article belongs to the Special Issue Advances in the Molecular Mechanisms in Gastrointestinal Tumorigenesis and Treatment)
Browse Figures
Versions Notes

Abstract

:
V-set domain-containing T-cell activation inhibitor 1 (aliases VTCN1, B7H4) participates in tumour immune escape by delivering inhibitory signals to T cells. The purpose of this article was to assess the B7H4 prognostic value in solid cancers. Three databases were searched for relevant articles. The main endpoints were overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS). Appropriate hazard ratios (HRs) were pooled. The R studio software (version 4.0.3) was used for data analysis. Thirty-one studies met the inclusion criteria. High expression of B7H4 was associated with worse OS (HR = 1.52, 95% CI: 1.37–1.68) but not with DSS (HR = 1.14, 95% CI: 0.49–2.63), RFS (HR = 1.77, 95% CI: 0.75–4.18), DFS (HR = 1.29, 95% CI: 0.8–2.09), or PFS (HR = 1.71, 95% CI: 0.91–3.2) in patients with solid cancers. High expression of B7H4 is associated with a poorer prognosis in patients with solid cancers. B7H4 is a promising prognostic biomarker and immunotherapeutic target for various solid cancers because of its activity in cancer immunity and tumourigenesis.

1. Introduction

1.1. B7H4 Expression and Function

B7H4 is a member of the B7 immune checkpoint family. The immune checkpoints are regulators of the immune system and are crucial for self-tolerance [1]. B7H4 is a coinhibitory ligand that exerts its function by suppressing the T cell effector function, while its molecule interaction on T cells remains unknown. B7H4 is broadly overexpressed in human cancers, including lung, liver, kidney, ovary, stomach, skin, pancreas, colorectal, and breast cancers, and is exploited by tumour in order to evade immune surveillance [2,3,4,5,6].

1.2. B7H4 in Solid Cancers

B7H4 is predominantly expressed on antigen-presenting cells (APCs) and tumour cells. Its heightened activity in cancer is associated with the increased infiltration of immunosuppressive cells and elevated production of regulatory T cells, leading to a reduced proliferation and effector function of CD4+ and CD8+ T cells [7]. Contrary to PD-L1, which is expressed in about 30% or even fewer patients and is associated with immunologically “hot” tumours, the expression of B7H4 marks a “cold” environment. The researchers observed, in some cases, a resistance to immune checkpoint inhibitor therapy, which mainly targets PD-1/PD-L1 and CTLA4 pathways [8,9,10]. This effect might be possibly explained by the activation of alternative immune checkpoints, e.g., B7H4. Aberrant B7x expression is associated with tumour necrosis, stage, grade, epithelial–mesenchymal transition (EMT), and survival outcomes such as progression free survival (PFS) and overall survival (OS), making it a potential blood biomarker in many cancers [11,12,13,14]. B7H4 has a soluble form called sB7H4 that can be detected in blood serum of cancer patients [15,16,17]. B7H4 expression is significantly limited in healthy tissues [18]. Elevated levels of sB7H4 were detected in the sera of gastric, hepatocellular, and renal cancer patients. In those studies, patients with higher levels of sB7H4 had a significantly shorter OS and higher probability of recurrence [15,16,17]. However, there is a very limited number of studies that evaluate the association of sB7H4 with cancer prognosis to conduct the meta-analysis. Instead, we performed the most comprehensive and up-to-date meta-analysis of B7H4 expression assessed by the immunohistochemistry method (IHC) and prognostic outcomes among solid cancers. Furthermore, we assessed all available surrogate endpoints, such as DFS, PFS, and RFS. Nowadays, B7H4 is extensively studied as a therapeutic target due to its role in immune system suppression in tumourigenesis [19,20,21]. Its expression is also distinct from the PD-1/PD-L1 pathways; thus, it provides the chance for effective therapies for the vast majority of cancer patients with B7H4-positive tumours [22,23]. Besides its therapeutic role, B7H4 might be a potentially good screening protein as it is secreted into the blood stream by cancer cells and paracancerous tissue, and it is mostly absent in healthy cells. On the other hand, it is not useful as a cancer-specific biomarker due to its overexpression in a variety of cancers. Study results also suggest that it might play a prognostic, predictive, and potentially monitoring role in cancers. This knowledge may be applied in the future in clinical decision making.

1.3. The Aim of the Study

As B7H4 is a relatively new immune checkpoint, its prognostic value in cancer prognosis has yet to be estimated. Currently available meta-analyses that tackle the topic of B7H4’s prognostic role were mostly conducted over 5 years ago. Moreover, as the number of studies was limited at that time, they are based on results from mixed methods of estimating B7H4 expression (ELISA, IHC) and sources of B7H4 expression (tissue, homogenates, blood sera) [24]. Additionally, some included different methods of prognosis estimation, such as the odds ratio (OR), rate ratio (RR), and hazard ratio (HR), to conduct the meta-analysis [25]. Furthermore, most studies were focused on the overall survival (OS) parameter, and two studies also evaluated disease-free survival (DFS) [25,26]. The disease-specific survival (DSS), progression-free survival (PFS), and recurrence-free survival (RFS) parameters have not yet been evaluated in meta-analyses. Therefore, we conducted a meta-analysis with one method of estimation of B7H4 expression (IHC) and prognosis (HR) to evaluate the prognostic value of B7H4 in parameters such as OS, DSS, DFS, PFS, and RFS among solid cancers.

2. Results

2.1. Search Results and Study Characteristics

A flow diagram showing our literature search and screening strategy is presented in Figure 1. A total of 850 articles were initially identified through database research. After removing 387 studies by applying automatic tools, the remaining 463 records were screened by reading the titles and abstracts. Further, 313 studies were excluded. One hundred and forty-nine studies were evaluated for eligibility, and, finally, 31 articles were included in the meta-analysis. The basic characteristics of the included studies are shown in Table 1. The studies were published between 2007 and 2023. They consisted of the following cancer types: OS—osteosarcoma [27], Pca—prostate cancer [28,29], CvC—cervical cancer [30,31], CCA—cholangiocarcinoma [13,32], PDAC—pancreatic ductal adenocarcinoma [33,34,35,36], UCC—urothelial cell carcinoma [36], HNSCC—head and neck squamous cell carcinoma [37,38], OC—ovarian cancer [39], ESCC—esophageal squamous cell carcinoma [28,40], BC—breast cancer [41,42], GC—gastric cancer [43,44], ECC—endometrial cancer [45], NSCLC—non-squamous cell lung carcinoma [46,47], RCC—renal cell carcinoma [48], and CRC—colorectal cancer [39,49,50,51,52]. The sample sizes ranged from 37 to 996, with a total of 6357 patients. B7H4 expression was measured by IHC in all cohorts. HRs and the corresponding 95% CIs of the assessed parameters were obtained by the multivariate analysis in 20 cohorts and univariate analysis or Kaplan–Meier curves in 11 cohorts. The NOS scores of all these studies were between 6 and 8 points, except for one article, which scored 5 points (Supplementary Material Table S4).

2.2. Results of Overall Survival Meta-Analysis

In total, 29 cohorts were qualified to assess the relation between B7H4 and OS, including both univariate and multivariate analyses. In the studies that reported both univariate and multivariate HRs, we used multivariate to diminish the risk of bias. The I (2) value was less than 50%, and the p value was less than 0.01, so the common effect model was used in the OS comparison. The results of the overall survival in solid tumours showed that high expression of B7H4 was associated with shorter OS (common effect model HR = 1.52, 95% CI: 1.37–1.68) (Figure 2A). We performed subgroup analysis to explore the potential factors that may cause heterogeneity. We classified the included cohorts and conducted subgroup analysis based on the cancer type, sample size, final score assessed in IHC analysis, and analysis method (Figure 2C,D, Supplementary Materials Figure S3). Subgroup analysis of gastrointestinal tumours revealed that B7H4 overexpression was correlated with poor OS, with an HR of 1.59, 95% CI: 1.27–1.98 (Figure 2C). The subgroup analysis by cancer type further confirmed the association of high B7H4 expression with shorter OS in patients with CCA (HR = 1.84, 95% CI: 1.37–2.48), ESCC (HR = 1.64, 95% CI: 1.15–2.32), CRC (HR = 1.59, 95% CI: 1.33–1.90), and GC (HR = 1.51, 95% CI: 1.12–2.04) but not in patients with PDAC (HR = 2.29, 95% CI: 0.93–5.61), RCC (HR = 1.77, 95% CI: 0.8–3.9), and NSCLC (HR = 1.11, 95% CI: 0.50–2.49) (Figure 2D). In addition, the subgroup analysis according to cancer type showed that there was significant heterogeneity within the PDAC and NSCLC subgroups (Figure 2D). When the subgroup analysis was performed according to the analysis method and final IHC score, the results changed. OS estimated by the univariate method did not support the B7H4 impact on survival unlike the multivariate method (HR = 1.26, 95% CI: 0.96–1.67 vs. HR = 1.61, 95% CI: 1.48–1.91) (Supplementary Materials Figure S3A). Similarly, the method of estimation of B7H4 expression impacted the results. The studies that assessed B7H4 IHC score with a cut-off > 3 had low heterogeneity and supported its association with worse OS (HR = 1.64, 95% CI: 1.41–1.90) (Supplementary Materials Figure S3C). Sample size did not change HRs significantly (Supplementary Materials Figure S3B).

2.3. Results of DSS, PFS, RFS, and DFS Meta-Analysis

The I (2) value was more than 50%, and the p value was less than 0.05, so the random-effects model was used in the comparison of DSS, DFS, PFS, and RFS (Figure 3, Figure 4, Figure 5 and Figure 6). The pooled results of the meta-analysis showed that a high expression of B7H4 was not associated with shorter DSS (HR = 1.14, 95% CI: 0.49–2.63), RFS (HR = 1.77, 95% CI: 0.75–4.18) (Figure 3A and Figure 6A, respectively), DFS (HR = 1.29, 95% CI: 0.8–2.09), or PFS (HR = 1.71, 95% CI: 0.91–3.2) (Figure 4A and Figure 5A, respectively) in the patients with solid cancers than a low expression of B7H4. In the sensitivity analysis, the PFS and RFS results would change if the Genova C 2019 NSCLC CTH cohort [47] and Zong L. 2022 [31] were omitted, respectively (Figure 5B and Figure 6B).
The p values of Begg’s test and Egger’s test for OS were above 0.05, which indicated no significant publication bias. Zong L. 2023, Piao L. 2018, Jikuya R. 2019 ccRCC cohort, and Zhao X. 2016 contributed the most to the overall heterogeneity in DSS, DFS, PFS, and RFS, respectively.

3. Methods

3.1. Data Sources and Search Strategy for Meta-Analysis

This systematic review and meta-analysis were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [54]. Embase (https://www.embase.com/ accessed on 1 July 2023), PubMed (https://pubmed.ncbi.nlm.nih.gov/ accessed on 10 July 2023), and the Cochrane Library (https://www.cochrane-library.com/ accessed on 1 August 2023) were searched for articles. The retrieval time was from the inception to 17 September 2023. This review was registered on the PROSPERO platform (CRD42023414613). The search strategy is described in detail in Supplementary Materials Tables S1–S3.

3.2. Inclusion and Exclusion Criteria

Inclusion criteria included patients diagnosed with solid cancer before enrolment, randomised controlled trials (RCTs) or observational studies, sufficient data about B7H4 expression evaluated by the immunohistochemical method (IHC), a clinical outcome with a provided hazard ratio (HR), or, in cases where the HR was not provided, the Kaplan–Meier curve with a number at risk table was accepted. The outcomes included overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), recurrence-free survival (RFS), and progression-free survival (PFS) (OS, DSS, DFS, PFS, RFS definitions: Supplementary Material Table S5). The exclusion criteria included a lack of sufficient data, non-solid and nervous system cancer, case reports, sequencing data studies, animal experiments, studies based on TCGA and other online available repository to avoid the duplication of data, meta-analyses, network meta-analyses, reviews, conference presentations, or study protocols.

3.3. Study Selection and Data Extraction

Two review authors (Miriam Dawidowicz and Agnieszka Kula) independently reviewed the titles and study abstracts with potential eligibility. The full texts of eligible studies were downloaded for further assessment. Three authors (Miriam Dawidowicz, Agnieszka Kula, Sylwia Mielcarska) independently extracted the following data: basic information, such as the first author, publication year, sample size, country, and study design; characteristics of patients, type, and stage of cancer; more detailed information regarding the clinical outcomes; information of cancer treatment, details about B7H4 expression location and cut-off value determining high expression, HR estimation method (univariate or multivariate analysis), and HR. Any disagreement was resolved by group discussion and consensus. We excluded results reported in only one study. If the study did not report an HR, but a survival curve with a number at risk table was published, the HR values were reconstructed using WebPlotDigitizer v4.7 and an algorithm was developed by Guyot P in R Studio [55]

3.4. Statistical Analysis for Meta-Analysis

To conduct all analyses, we used R software (version 4.0.3). For estimating the HR, multivariate analysis models were used; if not provided in the articles, univariate models were used. To estimate the heterogeneity, the chi-square Cochran’s Q-test and Higgins I2 statistics were performed. I2 values were interpreted as follows: 25–50%—low heterogeneity, 50–75%—moderate heterogeneity, above 75%—high heterogeneity according to J. P. Higgins and Thompson [56]. A fixed-effects model was used to pool the value of the HR and 95% confidence interval if I2 < 50% and p value > 0.05, indicating the lack of substantial heterogeneity. The random-effects model was applied when the significant heterogeneity was determined. In order to test the effect of the exclusion of one study each time, sensitivity analyses were performed. The publication bias assessments were conducted by a funnel plot and Begg’s and Egger’s tests.

3.5. Quality Assessment

Two reviewers (Miriam Dawidowicz, Sylwia Mielcarska) assessed the quality of eligible studies independently by using the Newcastle–Ottawa Quality Assessment Scale (NOS) [57]. The NOS assessed the quality of studies from the aspects of selection, comparability, and exposure, with a total score ranging from 0 to 9 points. More than 6 points was defined as high quality.

4. Discussion

B7H4 has been evaluated in a variety of solid tumours for its prognostic significance. In this meta-analysis, we aimed to summarise and compare the results of the published studies and extract valuable information that can be used in clinical decision making for human solid tumours. A total of 31 studies and 6357 patients were included. The results demonstrated that high B7H4 expression predicted poor OS in patients with cancers. The sensitivity analysis and publication bias proved that the results were reliable. However, heterogeneity existed among these studies. Considering the apparent heterogeneity, a subgroup analysis was performed.
The subgroup analysis indicated that a sample size, analysis method, and IHC score cut-off value did significantly reduce the heterogeneity among studies. Additionally, the subgroup analysis by cancer type revealed that B7H4 overexpression was correlated with poor OS in tumours, including CRC, GC, ESCC, and CCA, but not in PDAC, NSCLC, and RCC. Moreover, the subgroup analysis by cancer type also significantly reduced the heterogeneity within each subgroup. However, NSCLC and PDAC subgroup analyses by cancer type did not reduce heterogeneity. This might be explained by either high diversity of this cancer type, a small number of the included studies, or different methods of estimating the cut-off value for B7H4 expression.
Thus, this may suggest that cancer type was the main source of heterogeneity and that B7H4 expression may exert distinct effects in different cancer types. Studies with an IHC score cut-off value < 3 and univariate method of HR estimation did not support the relationship between high expression of B7H4 and OS. On the other hand, cut-off value was one of the heterogeneity sources. The studies where the expression of B7H4 was estimated by the most similar method had, as expected, low heterogeneity. Another factor that contributes to heterogeneity is the origin of the studied population. We did not analyse this factor in the subgroup analysis, but Qi Z-J and colleagues assessed that B7H4 was associated with worse OS in the Chinese population but not in the Japanese population [24]. The high expression of B7H4 was not significantly correlated with poor DSS, PFS, RFS, or DFS. However, the results might be inaccurate due to a relatively small number of studies that provided DSS, PFS, RFS, or DFS. Furthermore, the methods of estimating a high expression of B7H4 were highly varied in the included studies, and there were not enough studies to conduct an analysis for DSS, PFS, RFS, or DFS parameters in the subgroups to elucidate the impact of this factor.
B7H4 is not usually expressed in most normal immune cells and tissues; however, its overexpression in cancers often correlates with poor clinical outcomes and lower patient survival [9,10]. These findings were also confirmed in the previous meta-analysis. Nonetheless, there are some discrepancies between our results and the meta-analysis mentioned above. For instance, the HR in the meta-analysis conducted by Qi ZJ et al. and Song X et al. indicated poor OS in patients with PDAC, whereas our results did not support this effect of high B7H4 expression [24,26]. Secondly, patients with high B7-H4 had a significantly shorter DFS in the cohorts studied by Song X et al., whereas our analysis did not support it as well. These differences might be partially caused by including the team studies that evaluated the B7H4 expression by various methods, such as IHC and ELISA.
B7H4 is involved in tumour immunosuppressive mechanisms and is a checkpoint for inhibition [58]. Besides the prognostic value of B7H4, after PD-L1/PD-1 and CTLA-4, it is expected to be another ICB (immune checkpoint blockage) target [59]. High expression of B7H4 is associated with a poorer differentiation of tumour cells and epithelial–mesenchymal transition (EMT) of tumour cells [51,60]. Poorly differentiated tumour cells are associated with a higher presence of cancer stem cells (CSCs) in the tumour area, and this tumour phenotype is more prone to developing resistance to therapy [61]. B7H4 is expressed on CSCs, and its expression is associated with their maintenance [53,62]. Further, CSCs contribute to cancer resistance to ICI therapy [61].
Moreover, high expression of B7H4 is related to low infiltration levels of cytotoxic T lymphocytes [58,62]. The inhibition of B7H4 glycosylation has been reported to restore antitumour immunity in immune cold breast cancers [26]. These findings support the view that inhibiting the B7H4 function leads to restoring the proper T-cell function in patients with cancer. In addition, the B7H4 targeting strategy has the potential to possibly reduce the metastatic burden and tumour recurrence after therapy [61,63]. All these reasons indicate B7H4 to be an important and potent therapeutic target.
Given the limitations of this study, further well-designed studies that include evaluation of more tumour types with a larger sample size, a specifically determined cut-off value for high B7H4 expression by the IHC method, and detailed data about previously applied treatments are needed. A unified measuring method and cut-off value need to be established for prognostic analysis. The most comparable results were observed between studies that assessed B7H4 expression using an IHC score that was the percentage of positive cells and staining intensity, with a cut-off value for high expression above an IHC score of 3. In some studies, the HR and 95% CI were calculated by extracting data from Kaplan–Meier curves rather than directly from the original literature, which inevitably led to small statistical deviations. Another important matter is that researchers should provide sufficient data in their articles to enable including their results in further meta-analyses.

5. Conclusions

In summary, our meta-analysis provides comprehensive evidence that high B7H4 expression is associated with poor OS in solid tumours and might be used as a potential prognostic marker. However, high B7H4 expression was not related to OS in patients with PDAC, NSCLC, and RCC. The subgroup analysis that we performed helped to reduce the heterogeneity of results. The identified factors, such as cancer type, HR, and cut-off value estimation methods, significantly contributed to mitigating heterogeneity. These findings indicate the importance of evaluating different elements affecting the prognostic value of B7H4. Further studies performed to elucidate the mechanisms underlying the observed correlations and to confirm our results in larger, well-designed studies are required. Standardising methods for assessing B7H4 expression and establishing a uniform cut-off value for prognostic analysis are important steps towards improving the reliability and comparability of future studies. Therefore, more mechanistic studies are needed for further analysis.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms25095045/s1.

Author Contributions

Conceptualisation, M.D. and A.K.; methodology, M.D., A.K. and S.M.; software, S.M.; validation, S.M.; formal analysis, M.D. and S.M.; investigation, M.D.; data curation, A.K.; writing—original draft, M.D.; writing—review and editing, A.K., S.M., E.Ś. and D.W.; visualisation, M.D. and S.M.; supervision, E.Ś. and D.W. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author/s.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. He, X.; Xu, C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020, 30, 660–669. [Google Scholar] [CrossRef] [PubMed]
  2. Schildberg, F.A.; Klein, S.R.; Freeman, G.J.; Sharpe, A.H. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 2016, 44, 955–972. [Google Scholar] [CrossRef] [PubMed]
  3. Janakiram, M.; Shah, U.A.; Liu, W.; Zhao, A.; Schoenberg, M.P.; Zang, X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol. Rev. 2017, 276, 26–39. [Google Scholar] [CrossRef] [PubMed]
  4. Carreno, B.M.; Collins, M. The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 2002, 20, 29–53. [Google Scholar] [CrossRef] [PubMed]
  5. Collins, M.; Ling, V.; Carreno, B.M. The B7 family of immune-regulatory ligands. Genome Biol. 2005, 6, 223. [Google Scholar] [CrossRef] [PubMed]
  6. Ni, L.; Dong, C. New B7 Family Checkpoints in Human Cancers. Mol. Cancer Ther. 2017, 16, 1203–1211. [Google Scholar] [CrossRef]
  7. Mortezaee, K.; Majidpoor, J. Alternative immune checkpoints in immunoregulatory profile of cancer stem cells. Heliyon 2023, 9, e23171. [Google Scholar] [CrossRef] [PubMed]
  8. Chang, T.-P.; Polonskaya, Z.; Luna, X.; Martomo, S.; Zhang, Z.; Ng, S.; Patel, J.P.; Lu, D. 45P A novel bi-functional IL15 cytokine fusion antibody selected to kill B7-H4 positive tumor cells. Ann. Oncol. 2021, 32, S1391. [Google Scholar] [CrossRef]
  9. Jeon, H.; Vigdorovich, V.; Garrett-Thomson, S.C.; Janakiram, M.; Ramagopal, U.A.; Abadi, Y.M.; Lee, J.S.; Scandiuzzi, L.; Ohaegbulam, K.C.; Chinai, J.M.; et al. Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep. 2014, 9, 1089–1098. [Google Scholar] [CrossRef]
  10. Yuan, L.; Ye, J.; Fan, D. The B7-H4 gene induces immune escape partly via upregulating the PD-1/Stat3 pathway in non-small cell lung cancer. Hum. Immunol. 2020, 81, 254–261. [Google Scholar] [CrossRef]
  11. Yao, Y.; Ye, H.; Qi, Z.; Mo, L.; Yue, Q.; Baral, A.; Hoon, D.S.B.; Vera, J.C.; Heiss, J.D.; Chen, C.C.; et al. B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients. Clin. Cancer Res. 2016, 22, 2778–2790. [Google Scholar] [CrossRef] [PubMed]
  12. Krambeck, A.E.; Thompson, R.H.; Dong, H.; Lohse, C.M.; Park, E.S.; Kuntz, S.M.; Leibovich, B.C.; Blute, M.L.; Cheville, J.C.; Kwon, E.D. B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proc. Natl. Acad. Sci. USA 2006, 103, 10391–10396. [Google Scholar] [CrossRef]
  13. Xie, N.; Cai, J.-B.; Zhang, L.; Zhang, P.-F.; Shen, Y.-H.; Yang, X.; Lu, J.-C.; Gao, D.-M.; Kang, Q.; Liu, L.-X.; et al. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. Cell Death Dis. 2017, 8, 3205. [Google Scholar] [CrossRef] [PubMed]
  14. Thompson, R.H.; Zang, X.; Lohse, C.M.; Leibovich, B.C.; Slovin, S.F.; Reuter, V.E.; Cheville, J.C.; Blute, M.L.; Russo, P.; Kwon, E.D.; et al. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008, 68, 6054–6058. [Google Scholar] [CrossRef] [PubMed]
  15. Shi, H.; Ji, M.; Wu, J.; Zhou, Q.; Li, X.; Li, Z.; Zheng, X.; Xu, B.; Zhao, W.; Wu, C.; et al. Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer. World J. Surg. Oncol. 2014, 12, 188. [Google Scholar] [CrossRef] [PubMed]
  16. Zhang, C.; Li, Y.; Wang, Y. Diagnostic value of serum B7-H4 for hepatocellular carcinoma. J. Surg. Res. 2015, 197, 301–306. [Google Scholar] [CrossRef]
  17. Azuma, T.; Sato, Y.; Ohno, T.; Azuma, M.; Kume, H. Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma. PLoS ONE 2018, 13, e0199719. [Google Scholar] [CrossRef] [PubMed]
  18. Flies, D.B.; Chen, L. The new B7s: Playing a pivotal role in tumor immunity. J. Immunother. 2007, 30, 251–260. [Google Scholar] [CrossRef] [PubMed]
  19. Gray, E.; Ulrich, M.; Epp, A.; Younan, P.; Sahetya, D.; Hensley, K.; Allred, S.; Huang, L.-Y.; Hahn, J.; Gahnberg, K.; et al. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. J. Immunother. Cancer 2023, 11, e007572. [Google Scholar] [CrossRef]
  20. Gitto, S.B.; Whicker, M.; Davies, G.; Kumar, S.; Kinneer, K.; Xu, H.; Lewis, A.; Mamidi, S.; Medvedev, S.; Kim, H.; et al. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression. Clin. Cancer Res. 2024, 30, 1567–1581. [Google Scholar] [CrossRef]
  21. Podojil, J.R.; Glaser, A.P.; Baker, D.; Courtois, E.T.; Fantini, D.; Yu, Y.; Eaton, V.; Sivajothi, S.; Chiang, M.; Das, A.; et al. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma. Oncoimmunology 2020, 9, 1744897. [Google Scholar] [CrossRef]
  22. Song, X.; Zhou, Z.; Li, H.; Xue, Y.; Lu, X.; Bahar, I.; Kepp, O.; Hung, M.-C.; Kroemer, G.; Wan, Y. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers. Cancer Discov. 2020, 10, 1872–1893. [Google Scholar] [CrossRef] [PubMed]
  23. Altan, M.; Pelekanou, V.; Schalper, K.A.; Toki, M.; Gaule, P.; Syrigos, K.; Herbst, R.S.; Rimm, D.L. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clin. Cancer Res. 2017, 23, 5202–5209. [Google Scholar] [CrossRef] [PubMed]
  24. Qi, Z.-J.; Yu, D.; Chen, C.-H.; Jiang, H.; Li, R.; Kang, Y.-M. The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis. Int. J. Biol. Markers 2019, 34, 373–380. [Google Scholar] [CrossRef] [PubMed]
  25. Meng, Z.; Wang, F.; Zhang, Y.; Li, S.; Wu, H. B7-H4 as an independent prognostic indicator of cancer patients: A meta-analysis. Oncotarget 2017, 8, 68825–68836. [Google Scholar] [CrossRef] [PubMed]
  26. Song, X.; Shao, Y.; Gu, W.; Xu, C.; Mao, H.; Pei, H.; Jiang, J. Prognostic role of high B7-H4 expression in patients with solid tumors: A meta-analysis. Oncotarget 2016, 7, 76523–76533. [Google Scholar] [CrossRef]
  27. Dong, Q.; Ma, X. B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma. Biomed Res. Int. 2015, 2015, 156432. [Google Scholar] [CrossRef] [PubMed]
  28. Li, H.; Piao, L.; Liu, S.; Cui, Y.; Xuan, Y. B7-H4 is a potential prognostic biomarker of prostate cancer. Exp. Mol. Pathol. 2020, 114, 104406. [Google Scholar] [CrossRef] [PubMed]
  29. Zang, X.; Thompson, R.H.; Al-Ahmadie, H.A.; Serio, A.M.; Reuter, V.E.; Eastham, J.A.; Scardino, P.T.; Sharma, P.; Allison, J.P. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. USA 2007, 104, 19458–19463. [Google Scholar] [CrossRef]
  30. Zong, L.; Zhang, Q.; Zhou, Y.; Kong, Y.; Yu, S.; Chen, J.; Zhang, Y.; Xiang, Y. Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix. J. Immunol. Res. 2020, 2020, 1283632. [Google Scholar] [CrossRef]
  31. Zong, L.; Gu, Y.; Zhou, Y.; Kong, Y.; Mo, S.; Yu, S.; Xiang, Y.; Chen, J. Expression of B7 family checkpoint proteins in cervical cancer. Mod. Pathol. 2022, 35, 786–793. [Google Scholar] [CrossRef] [PubMed]
  32. Zhao, X.; Guo, F.; Li, Z.; Jiang, P.; Deng, X.; Tian, F.; Li, X.; Wang, S. Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma. Oncol. Rep. 2016, 36, 419–427. [Google Scholar] [CrossRef] [PubMed]
  33. Xu, H.; Chen, X.; Tao, M.; Chen, K.; Chen, C.; Xu, G.; Li, W.; Yuan, S.; Mao, Y. B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer. Oncol. Lett. 2016, 11, 1841–1846. [Google Scholar] [CrossRef] [PubMed]
  34. Tsiaousidou, A.; Tsaroucha, A.K.; Lambropoulou, M.; Pitiakoudis, M.; Polychronidis, A.; Chatzitheoklitos, E.; Romanidis, K.; Simopoulos, C. Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma. Clin. Exp. Med. 2016, 16, 351–356. [Google Scholar] [CrossRef]
  35. Loch, F.N.; Kamphues, C.; Beyer, K.; Schineis, C.; Rayya, W.; Lauscher, J.C.; Horst, D.; Dragomir, M.P.; Schallenberg, S. The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci. 2023, 24, 2160. [Google Scholar] [CrossRef] [PubMed]
  36. Fan, M.; Zhuang, Q.; Chen, Y.; Ding, T.; Yao, H.; Chen, L.; He, X.; Xu, X. B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma. Int. J. Clin. Exp. Pathol. 2014, 7, 6768–6775. [Google Scholar] [PubMed]
  37. Borgmann, M.; Oetting, A.; Meyer, F.; Möckelmann, N.; Droste, C.; von Bargen, C.M.; Möller-Koop, C.; Witt, M.; Borgmann, K.; Rothkamm, K.; et al. The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2023, 149, 3383–3393. [Google Scholar] [CrossRef] [PubMed]
  38. Wu, L.; Deng, W.-W.; Yu, G.-T.; Mao, L.; Bu, L.-L.; Ma, S.-R.; Liu, B.; Zhang, W.-F.; Sun, Z.-J. B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma. Cancer Immunol. Immunother. 2016, 65, 1035–1045. [Google Scholar] [CrossRef] [PubMed]
  39. Liang, M.; Li, J.; Wang, D.; Li, S.; Sun, Y.; Sun, T.; Zhang, J.; Chen, X.; Li, Q.; Sun, S. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China’s Heilongjiang province. Tumour Biol. 2014, 35, 55–60. [Google Scholar] [CrossRef]
  40. Chen, L.-j.; Sun, J.; Wu, H.-y.; Zhou, S.-m.; Tan, Y.; Tan, M.; Shan, B.-e.; Lu, B.-f.; Zhang, X.-g. B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 2011, 60, 1047–1055. [Google Scholar] [CrossRef]
  41. Liang, L.; Jiang, Y.; Chen, J.-S.; Niu, N.; Piao, J.; Ning, J.; Zu, Y.; Zhang, J.; Liu, J. B7-H4 expression in ovarian serous carcinoma: A study of 306 cases. Hum. Pathol. 2016, 57, 1–6. [Google Scholar] [CrossRef] [PubMed]
  42. Wang, L.; Yang, C.; Liu, X.-B.; Wang, L.; Kang, F.-B. B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer. Cancer Cell Int. 2018, 18, 100. [Google Scholar] [CrossRef] [PubMed]
  43. Geng, Y.; Wang, H.; Lu, C.; Li, Q.; Xu, B.; Jiang, J.; Wu, C. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int. J. Clin. Oncol. 2015, 20, 273–281. [Google Scholar] [CrossRef] [PubMed]
  44. Arigami, T.; Uenosono, Y.; Ishigami, S.; Hagihara, T.; Haraguchi, N.; Natsugoe, S. Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J. Surg. 2011, 35, 2051–2057. [Google Scholar] [CrossRef]
  45. Zong, L.; Yu, S.; Mo, S.; Sun, Z.; Lu, Z.; Chen, J.; Xiang, Y. B7-H4 Further Stratifies Patients With Endometrial Cancer Exhibiting a Nonspecific Molecular Profile. Arch. Pathol. Lab. Med. 2023, 147, 1288–1297. [Google Scholar] [CrossRef]
  46. Parra, E.R.; Villalobos, P.; Zhang, J.; Behrens, C.; Mino, B.; Swisher, S.; Sepesi, B.; Weissferdt, A.; Kalhor, N.; Heymach, J.V.; et al. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J. Thorac. Oncol. 2018, 13, 779–791. [Google Scholar] [CrossRef] [PubMed]
  47. Genova, C.; Boccardo, S.; Mora, M.; Rijavec, E.; Biello, F.; Rossi, G.; Tagliamento, M.; Dal Bello, M.G.; Coco, S.; Alama, A.; et al. Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. J. Clin. Med. 2019, 8, 1566. [Google Scholar] [CrossRef]
  48. Jikuya, R.; Kishida, T.; Sakaguchi, M.; Yokose, T.; Yasui, M.; Hashizume, A.; Tatenuma, T.; Mizuno, N.; Muraoka, K.; Umemoto, S.; et al. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma. Cancer Immunol. Immunother. 2020, 69, 2041–2051. [Google Scholar] [CrossRef]
  49. Feng, Y.; Yang, Z.; Zhang, C.; Che, N.; Liu, X.; Xuan, Y. B7-H4 induces epithelial-mesenchymal transition and promotes colorectal cancer stemness. Pathol. Res. Pract. 2021, 218, 153323. [Google Scholar] [CrossRef]
  50. Ding, S.; Lv, X.; Liu, Z.; Zhan, S.; Xu, Y.; Zhang, X.; Liu, C.; Cao, L. Overexpression of B7-H4 is associated with infiltrating immune cells and poor prognosis in metastatic colorectal cancer. Int. Immunopharmacol. 2021, 90, 107144. [Google Scholar] [CrossRef]
  51. Yan, X.; Hong, B.; Feng, J.; Jin, Y.; Chen, M.; Li, F.; Qian, Y. B7-H4 is a potential diagnostic and prognostic biomarker in colorectal cancer and correlates with the epithelial-mesenchymal transition. BMC Cancer 2022, 22, 1053. [Google Scholar] [CrossRef] [PubMed]
  52. Cao, H.; Wang, Q.; Gao, Z.; Xu, X.; Lu, Q.; Wu, Y. Clinical value of detecting IQGAP3, B7-H4 and cyclooxygenase-2 in the diagnosis and prognostic evaluation of colorectal cancer. Cancer Cell Int. 2019, 19, 163. [Google Scholar] [CrossRef] [PubMed]
  53. Piao, L.; Yang, Z.; Jin, J.; Ni, W.; Qi, W.; Xuan, Y. B7H4 is associated with stemness and cancer progression in esophageal squamous cell carcinoma. Hum. Pathol. 2018, 80, 152–162. [Google Scholar] [CrossRef] [PubMed]
  54. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Syst. Rev. 2021, 10, 89. [Google Scholar] [CrossRef] [PubMed]
  55. Guyot, P.; Ades, A.E.; Ouwens, M.J.N.M.; Welton, N.J. Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 2012, 12, 9. [Google Scholar] [CrossRef] [PubMed]
  56. Higgins, J.P.T.; Thompson, S.G.; Spiegelhalter, D.J. A re-evaluation of random-effects meta-analysis. J. R. Stat. Soc. Ser. A Stat. Soc. 2009, 172, 137–159. [Google Scholar] [CrossRef] [PubMed]
  57. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25, 603–605. [Google Scholar] [CrossRef] [PubMed]
  58. Jing, Z.-L.; Liu, G.-L.; Zhou, N.; Xu, D.-Y.; Feng, N.; Lei, Y.; Ma, L.-L.; Tang, M.-S.; Tong, G.-H.; Tang, N.; et al. Interferon-γ in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells. Sci. Rep. 2024, 14, 6053. [Google Scholar] [CrossRef] [PubMed]
  59. Pulanco, M.C.; Madsen, A.T.; Tanwar, A.; Corrigan, D.T.; Zang, X. Recent advancements in the B7/CD28 immune checkpoint families: New biology and clinical therapeutic strategies. Cell. Mol. Immunol. 2023, 20, 694–713. [Google Scholar] [CrossRef]
  60. Mizuno, T.; Kamai, T.; Tsuzuki, T.; Nishihara, D.; Kijima, T.; Arai, K.; Yoshida, K.-I. Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma. Cancer Immunol. Immunother. 2022, 71, 565–578. [Google Scholar] [CrossRef]
  61. Mortezaee, K. Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. J. Biochem. Mol. Toxicol. 2021, 35, e22708. [Google Scholar] [CrossRef] [PubMed]
  62. Panaccione, A.; Guo, Y.; Yarbrough, W.G.; Ivanov, S.V. Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers. Clin. Breast Cancer 2017, 17, 298–306.e7. [Google Scholar] [CrossRef] [PubMed]
  63. Galazka, K.; Opławski, M.; Windorbska, W.; Skret-Magierlo, J.; Koper, K.; Basta, P.; Mach, P.; Dutch-Wicherek, M.; Mazur, A.; Wicherek, L. The immunohistochemical analysis of antigens such as RCAS1 and B7H4 in the cervical cancer nest and within the fibroblasts and macrophages infiltrating the cancer microenvironment. Am. J. Reprod. Immunol. 2012, 68, 85–93. [Google Scholar] [CrossRef] [PubMed]
Ijms 25 05045 g001
Figure 1. Study selection flowchart.
Figure 1. Study selection flowchart.
Ijms 25 05045 g001
Ijms 25 05045 g002
Figure 2. Forest plots of studies evaluating HRs of high B7H4 expression and overall survival in solid tumours and the subgroup analysis. (A) Forest plot of overall survival among all solid tumours. (B) One−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and overall survival in solid tumours. (C) Forest plot of overall survival in gastrointestinal cancers. (D) Forest plot of overall survival in cancer type subgroups.
Figure 2. Forest plots of studies evaluating HRs of high B7H4 expression and overall survival in solid tumours and the subgroup analysis. (A) Forest plot of overall survival among all solid tumours. (B) One−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and overall survival in solid tumours. (C) Forest plot of overall survival in gastrointestinal cancers. (D) Forest plot of overall survival in cancer type subgroups.
Ijms 25 05045 g002
Ijms 25 05045 g003
Figure 3. (A) Forest plot of studies evaluating HRs of high B7H4 expression and disease−specific survival (DSS) in solid tumours. (B) One−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and DSS in solid tumours.
Figure 3. (A) Forest plot of studies evaluating HRs of high B7H4 expression and disease−specific survival (DSS) in solid tumours. (B) One−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and DSS in solid tumours.
Ijms 25 05045 g003
Ijms 25 05045 g004
Figure 4. (A) Forest plot of studies evaluating HRs of high B7H4 expression and disease−free survival (DFS) in solid tumours. (B) One-−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and DFS in solid tumours.
Figure 4. (A) Forest plot of studies evaluating HRs of high B7H4 expression and disease−free survival (DFS) in solid tumours. (B) One-−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and DFS in solid tumours.
Ijms 25 05045 g004
Ijms 25 05045 g005
Figure 5. (A) Forest plot of studies evaluating HRs of high B7H4 expression and progression−free survival (PFS) in solid tumours. (B) One−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and PFS in solid tumours.
Figure 5. (A) Forest plot of studies evaluating HRs of high B7H4 expression and progression−free survival (PFS) in solid tumours. (B) One−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and PFS in solid tumours.
Ijms 25 05045 g005
Ijms 25 05045 g006
Figure 6. (A) Forest plot of studies evaluating HRs of high B7H4 expression and recurrence−free survival (RFS) in solid tumours. (B) One−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and RFS in solid tumours.
Figure 6. (A) Forest plot of studies evaluating HRs of high B7H4 expression and recurrence−free survival (RFS) in solid tumours. (B) One−leave meta−analysis for investigating the effects of particular studies on the association between B7H4 expression and RFS in solid tumours.
Ijms 25 05045 g006
Table 1. Basic characteristics.
Table 1. Basic characteristics.
AuthorYearPatient SourceSample SizeMethodCancer TypeB7H4 + ExpressionCut-offCell TypesOutcomeHR Multivare (M)/Univare (U)NOS
1[49]2021China98IHCCRC0.69>0%tumour cellsOS/DFSreportedU/M8
2[44]2011Japan120IHCGC0.94staining 0, +/++, +++ tumour cellsOSreportedU/M7
3[50]2021China110IHCCRC0.51H score > 85tumour cellsOSreportedU6
4[40]2011China112IHCESCC0.95H score > 160tumour cellsOSreportedU/M7
5[13]2017China140IHCCCA0.45Final score > 3all types of cellsOSreportedU/M7
6[38]2016China164IHCHNSCC1.00H score > 88all types of cellsOSreportedU5
7[27]2015China104IHCOS0.7Final score > 3all types of cellsOSreportedU/M7
8[30]2020China50IHCCvC0.32>5%tumour cellsOS/DFSreportedU7
9[41]2016China293IHCOC0.91Final score > 2, tumour cellsOS/DFSreportedU7
10[36]2014China62IHCUCC0.76Final score > 4all types of cellsOSreportedU/M6
11[42]2018China59IHCBC0.91Final score > 3tumour cells OSreportedU/M7
12[28]2020China152IHCPCa0.67IHC score > 1, all types of cellsOSreportedU/M6
13[39]2014China185IHCCRC0.63Final score > 3tumour cells OS/DFSreportedU7
14[53]2018Korea158IHCESCC0.54IHC score > 1, all types of cellsOS/DFSreportedU/M8
15[46]2018USA123IHCNSCLCNA>1, 38 mediana, % of tumor cells tumour cells OSreportedU6
16[46]2018USA61IHCNSCLCNA>1, 59 mediana, % of tumor cells tumour cells OSreportedU6
17[33]2016China40IHCPDAC0.75>10%tumour cells OSreportedM7
18[47]2019Italy44IHCNSCLC0.39>0%tumour cells OS/PFSreportedU/M8
19[47]2019Italy37IHCNSCLC0.4>10%tumour cells OS/PFSreportedU/M8
20[34]2016Greece41IHCPDAC0.39>0%tumour cells OSreportedU/M7
21[32]2016China110IHCCCA0.49Final score > 3tumour cells OS/RFSreportedM8
22[51]2022China996IHCCRC0.61Final score > 3tumour cells OSreportedM7
23[52]2019China118IHCCRC0.56Final score > 3all types of cellsOSreportedM7
24[29]2007USA814IHCPCa0.8>5% + strong intensitytumour cellsRFS/DSSreportedU7
25[31]2022China605IHCCvC0.45≥5%tumour cellsRFS/DSSreportedU7
26[45]2023China833IHCECC0.71>0%tumour cellsRFS/DSSreportedU/M8
27[48]2020Japan83IHCRCC0.40median NAtumour cells or immune cellsOS/PFSreportedU/M8
28[48]2020Japan69IHCRCC0.48median NAtumour cells or immune cellsOS/PFSreportedU/M8
29[43]2015China100IHCGC0.71Final score > 2 OSreportedU/M7
30[35]2023Germany68IHCPDAC0.22>1%tumour cellsOSpooledU6
31[37]2022Germany408IHCHNSCC0.97≤ 70% + intensity 1tumour cellsOSpooledU6
Immunohistochemistry (IHC), overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), disease-specific survival (DSS), recurrence-free survival (RFS), adenocarcinoma (ADC), squamous cell carcinoma (SCC), nivolumab cohort (N), chemotherapy cohort (CTH), OS—osteosarcoma, Pca—prostate cancer, CvC—cervical cancer, CCA—cholangiocarcinoma, PDAC—pancreatic ductal adenocarcinoma, UCC—urothelial cell carcinoma, HNSCC—head and neck squamous cell carcinoma, OC—ovarian cancer, ESCC—esophageal squamous cell carcinoma, BC—breast cancer, GC—gastric cancer, ECC—endometrial cancer, NSCLC—non-squamous cell lung carcinoma, RCC—renal cell carcinoma, and CRC—colorectal cancer.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Dawidowicz, M.; Kula, A.; Mielcarska, S.; Świętochowska, E.; Waniczek, D. Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci. 2024, 25, 5045. https://doi.org/10.3390/ijms25095045

AMA Style

Dawidowicz M, Kula A, Mielcarska S, Świętochowska E, Waniczek D. Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2024; 25(9):5045. https://doi.org/10.3390/ijms25095045

Chicago/Turabian Style

Dawidowicz, Miriam, Agnieszka Kula, Sylwia Mielcarska, Elżbieta Świętochowska, and Dariusz Waniczek. 2024. "Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis" International Journal of Molecular Sciences 25, no. 9: 5045. https://doi.org/10.3390/ijms25095045

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop